Rituximab in kidney disease and transplant

Rituximab is a chimeric monoclonal antibody that binds to CD20 antigen of B‐cells. It depletes the level of mature B‐cells by various mechanisms such as mediation of antibody‐dependent cellular cytotoxicity, complement‐dependent cytotoxicity, and B‐cell apoptosis. Rituximab is a USFDA approved drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauhan, Kajal, Mehta, Anita A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600632/
https://www.ncbi.nlm.nih.gov/pubmed/31392300
http://dx.doi.org/10.1002/ame2.12064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600632/
https://www.ncbi.nlm.nih.gov/pubmed/31392300
http://dx.doi.org/10.1002/ame2.12064

Ejemplares similares